Drug Search Results
More Filters [+]

CA-125

Alternative Names: ca-125, ca125, ca 125
Latest Update: 2024-10-24
Latest Update Note: News Article

Product Description

The CA125 monoclonal antibodies recognize epitopes in the protein core of the CA125 antigen. These monoclonal antibodies show high specificity for ovarian cancer, and can be used for development of fast and sensitive homologous or heterologous assays. (Sourced from: https://www.fujirebio.com/en/products-solutions/ca125-antibodies)

Mechanisms of Action: MUC16 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Fundación para la Investigación del Hospital Clínico de Valencia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CA-125

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Heart Failure|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SURVIVE

N/A

Recruiting

Breast Cancer

2035-12-01

NU 99G8

N/A

Recruiting

Sarcoma|Cervical Cancer|Fallopian Tube Cancer|Ovarian Cancer|Vaginal Cancer|Myofibroma|Breast Cancer|Endometrial Cancer|Vulvar Cancer|Uterine Cancer|Leiomyoma

2030-12-01

ChiCTR2400089195

N/A

Recruiting

Endometrial Cancer

2027-05-31

ChiCTR2400079698

N/A

Not yet recruiting

Breast Cancer

2026-12-31

Recent News Events